SUL-150 Limits Vascular Remodeling and Ventricular Failure in Pulmonary Arterial Hypertension
International Journal of Molecular Sciences · 25.07.2025 · 26 (15) · 7181
DOI: 10.3390/ijms26157181 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.07.2025. Verfasst von Lysanne M Jorna und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric and Congenital Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1 (CA40), 9713 GZ Groning…. Hauptthemen laut MEDLINE: Vascular Remodeling, Pulmonary Arterial Hypertension, Heart Failure, Ventricular Dysfunction, Right. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NETHERLANDS CARDIOVASCULAR RESEARCH INITIATIVE (CVON), Dutch Research Council, NETHERLANDS CARDIOVASCULAR RESEARCH INITIATIVE (CVON): the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organization….
Abstract (Originalsprache)
Pulmonary arterial hypertension (PAH) is a rare, progressive, and incurable disease characterized by an elevated pulmonary blood pressure, extensive remodeling of the pulmonary vasculature, increased pulmonary vascular resistance, and culminating in right ventricular failure. Mitochondrial dysfunction has a major role in the pathogenesis of PAH and secondary right ventricular failure, and its targeting may offer therapeutic benefit. In this study, we provide proof-of-concept for the use of the mitochondrially active drug SUL-150 to treat PAH. PAH was induced in rats by monocrotaline, followed by the placement of an aortocaval shunt one week later. The mitoprotective compound SUL-150 (~6 mg·kg−1·day−1) or vehicle was administered intraperitoneally via osmotic minipump for 28 days, implanted at the time of aortocaval shunt placement. Vehicle-treated PAH rats had dyspnea and showed pulmonary artery remodeling with increased responsiveness to phenylephrine, in addition to remodeling of the intrapulmonary arterioles. SUL-150 administration mitigated the dyspnea and the remodeling responses. Vehicle-treated PAH rats developed right ventricular hypertrophy, fibrosis, and failure. SUL-150 administration precluded cardiomyocyte hypertrophy and inhibited ventricular fibrogenesis. Right ventricular failure in vehicle-treated PAH rats induced mitochondrial loss and dysfunction associated with a decrease in mitophagy. SUL-150 was unable to prevent the mitochondrial loss but improved mitochondrial health in the right ventricle, which culminated in the preservation of right ventricular function. We conclude that SUL-150 improves PAH-associated morbidity by the amelioration of pulmonary vascular remodeling and right ventricular failure and may be considered a promising therapeutic candidate to slow disease progression in pulmonary arterial hypertension and secondary right ventricular failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric and Congenital Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1 (CA40), 9713 GZ Groningen, The Netherlands.
- Laboratory for Cardiovascular Regenerative Medicine, Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Hanzeplein 1 (EA11), 9713 GZ Groningen, The Netherlands.
- Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Hanzeplein 1 (AP50), 9713 GZ Groningen, The Netherlands.
- Clinical Research Unit, Comenius University Science Park, Comenius University Bratislava, 841 04 Bratislava, Slovakia.
- Department of Experimental Pharmacology, Medical Faculty Mannheim, University of Heidelberg, Ludolf Krehlstrasse 13-17, 68167 Mannheim, Germany.
- Department of Microbiology and Immunology, University of Veterinary Medicine and Pharmacy, Komenského 73, 041 81 Košice, Slovakia.
ORCID-Profile: Lysanne M Jorna, Dalibor Nakládal, Soňa Tkáčiková, Robert H Henning, Martin C Harmsen, Rolf M F Berger, Guido Krenning
Förderung
- NETHERLANDS CARDIOVASCULAR RESEARCH INITIATIVE (CVON)
- Dutch Research Council
- NETHERLANDS CARDIOVASCULAR RESEARCH INITIATIVE (CVON): the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organization…
- NETHERLANDS ORGANIZATION FOR SCIENTIFIC RESEARCH (NWO) and the NETHERLANDS ORGANIZATION FOR HEALTH RESEARCH AND DEVELOPMENT
Zitieren
APA
Jorna, L. M., Nakládal, D., van Heuveln, J. N., van der Feen, D. E., Hagdorn, Q. A. J., Bossers, G. P. L., van Oosten, A., Weij, M., Tkáčiková, L., Tkáčiková, S., Henning, R. H., Harmsen, M. C., Berger, R. M. F., & Krenning, G. (2025). SUL-150 Limits Vascular Remodeling and Ventricular Failure in Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 26(15), 7181. https://doi.org/10.3390/ijms26157181
Vancouver
Jorna LM, Nakládal D, van Heuveln JN, van der Feen DE, Hagdorn QAJ, Bossers GPL, et al. SUL-150 Limits Vascular Remodeling and Ventricular Failure in Pulmonary Arterial Hypertension. International Journal of Molecular Sciences. 2025;26(15):7181. doi:10.3390/ijms26157181
BibTeX
@article{Jorna2025,
author = {Jorna, Lysanne M and Nakládal, Dalibor and van Heuveln, Johannes N and van der Feen, Diederik E and Hagdorn, Quint A J and Bossers, Guido P L and van Oosten, Annemieke and Weij, Michel and Tkáčiková, Ludmila and Tkáčiková, Soňa and Henning, Robert H and Harmsen, Martin C and Berger, Rolf M F and Krenning, Guido},
title = {SUL-150 Limits Vascular Remodeling and Ventricular Failure in Pulmonary Arterial Hypertension},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {15},
pages = {7181},
doi = {10.3390/ijms26157181}
}
EUVIMED